Column Considers Drug Pricing in U.S., COVID-19 Vaccine

A recent column published in the Los Angeles Times looks at how the U.S. handles drug pricing, and what that could mean for a COVID-19 vaccine.

“The harsh reality is that the United States is one of the few developed countries that allow pharmaceutical companies to charge whatever they want for prescription drugs — even when production costs are just a fraction of the list price,” David Lazarus, Los Angeles Times business columnist, writes.

To read the full column, click here.